H. Lundbeck, Merck & Co., Inc. and Lundbeck announce update in submission plans for U.S. approval of gaboxadol

Merck & Co., Inc. and H. Lundbeck A/S today announced that submission of a New Drug Application (NDA) for gaboxadol with the U.S. Food and Drug Administration will no longer occur in the first quarter of 2007. The companies plan to submit the NDA in mid-2007.